Leerink Partnrs Decreases Earnings Estimates for Pharvaris

Pharvaris (NASDAQ:PHVS) – Equities researchers at Leerink Partnrs lowered their FY2026 EPS estimates for Pharvaris in a research note issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($2.87) per share for the year, down from their prior estimate of ($2.34). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $19.32 on Wednesday. The firm has a market cap of $1.01 billion, a PE ratio of -6.90 and a beta of -3.06. The firm’s fifty day moving average is $19.37 and its 200-day moving average is $19.35. Pharvaris has a 52 week low of $15.21 and a 52 week high of $33.00.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds have recently bought and sold shares of the company. Public Employees Retirement System of Ohio bought a new position in Pharvaris during the third quarter worth $57,000. Barclays PLC bought a new position in Pharvaris during the third quarter worth $106,000. Geode Capital Management LLC raised its stake in Pharvaris by 18.4% during the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after buying an additional 5,753 shares during the last quarter. HighVista Strategies LLC raised its stake in Pharvaris by 35.9% during the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after buying an additional 6,018 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in Pharvaris during the third quarter worth $526,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.